<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        51-498-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        L-CET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOCETIRIZINE DIHYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OMAN PHARMACEUTICAL PRODUCTS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R06AE09 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What L-Cet is and what it is used for</strong></p><p>Levocetirizine dihydrochloride is the active ingredient of L-Cet. L-Cet is an antiallergic medication.</p><p>For the treatment of signs of illness (symptoms) associated with:</p><p>&bull; allergic rhinitis (including persistent allergic rhinitis);</p><p>&bull; nettle rash (urticaria).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>2. Before you take L-Cet</strong></p><p style="text-align:justify"><strong>&nbsp;Do not take L-Cet</strong></p><p style="text-align:justify">- if you are allergic (hypersensitive) to the active substance, levocetirizine dihydrochloride, or to an antihistamine, or to methyl parahydroxybenzoate, propyl parahydroxybenzoate, or any of the other ingredients of L-Cet (see &lsquo;What L-Cet contains&rsquo;).</p><p style="text-align:justify">- if you have a severe impairment of kidney function (severe renal failure with creatinine clearance below 10 ml/min).</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Take special care with L-Cet</strong></p><p style="text-align:justify">The use of L-Cet is not recommended for infants and children under 2 years.</p><p style="text-align:justify"><strong>&nbsp;Taking other medicines</strong></p><p style="text-align:justify">Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p style="text-align:justify"><strong>&nbsp;Taking L-Cet with food and drink</strong></p><p style="text-align:justify">Caution is advised if L-Cet is taken at the same time as alcohol. In sensitive patients, taking cetirizine or levocetirizine with alcohol or other medicines that act on the brain may affect alertness.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Pregnancy and breast-feeding</strong></p><p style="text-align:justify">Tell your doctor if you are pregnant, trying to get pregnant or breastfeeding.</p><p style="text-align:justify">Ask your doctor or pharmacist for advice before taking any medicine.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Driving and using machines</strong></p><p style="text-align:justify">Some patients being treated with L-Cet may experience drowsiness, tiredness and exhaustion. Use caution when driving or operating machinery untill you know how this medicine affects you. However, special tests have revealed no impairment of mental alertness, the ability to react or the ability to drive in healthy test persons after taking levocetirizine in the recommended dosage.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Important information about some of the ingredients of L-Cet</strong></p><p style="text-align:justify">- This medicine contains maltitol. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking L-Cet.</p><p style="text-align:justify">- Methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed), such as headache, stomach upset, and diarrhoea.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>3. How to take L-Cet</strong></p><p style="text-align:justify">Always take L-Cet exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p style="text-align:justify"><strong>&nbsp;Dosage:</strong></p><p style="text-align:justify">The usual dose is:</p><p style="text-align:justify">- Adults and children from the age of 6 years: 10 ml solution once daily.</p><p style="text-align:justify">- Children from the age of 2 to 6 years: 2.5 ml solution twice daily.</p><p style="text-align:justify">The administration of L-Cet to infants and toddlers aged less than 2 years is not recommended.</p><p style="text-align:justify"><strong>&nbsp;Special dosage instructions for specific populations:</strong></p><p style="text-align:justify">Patients with impaired kidney function may be given a lower dose according to the severity of their kidney disease, and in children the dose will also be chosen on the basis of body weight; the dose will be determined by your doctor.</p><p style="text-align:justify">Patients who have severe impairment of kidney function must not take L-Cet.</p><p style="text-align:justify">Patients who only have impaired liver function should take the usual prescribed dose.</p><p style="text-align:justify">Patients who have both impaired liver and kidney function may be given a lower dose depending on the severity of the kidney disease, and in children the dose will also be chosen on the basis of body weight; the dose will be determined by your doctor.</p><p style="text-align:justify">No adaptation of the dose is necessary in elderly patients, provided their renal function is normal.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>How and when should you take L-Cet ?</strong></p><p style="text-align:justify">For oral use only.</p><p style="text-align:justify">A measuring cup is supplied with the pack. The solution can be taken undiluted or diluted in a glass of water.</p><p style="text-align:justify">L-Cet may be taken with or without food.</p><p style="text-align:justify">The oral intake of the drug should be performed right after dilution.</p><p style="text-align:justify">Rinse the cup with water after every use.</p><p style="text-align:justify"><strong>&nbsp;</strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:246.75pt;height:2in;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:\Users\reg05\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="329" height="192" src="file:///C:\Users\reg05\AppData\Local\Temp\msohtmlclip1\01\clip_image002.jpg" /></p><p style="text-align:justify"><strong>&nbsp;</strong><strong style="text-align:unset">&nbsp;</strong></p><p style="text-align:justify"><strong>How long should you take L-Cet?</strong></p><p style="text-align:justify">The duration of use depends on the type, duration and course of your complaints and is determined by your physician.</p><p style="text-align:justify"><strong>&nbsp;If you take more L-Cet than you should</strong></p><p style="text-align:justify">If you take more L-Cet than you should, somnolence can occur in adults. Children may initially show excitation and restlessness followed by somnolence.</p><p style="text-align:justify">If you think you have taken an overdose of L-Cet, please tell your doctor who will then decide what action should be taken.</p><p style="text-align:justify"><strong>&nbsp;If you forget to take L-Cet</strong></p><p style="text-align:justify">If you forget to take L-Cet, or if you take a dose lower than that prescribed by your doctor, do not take a double dose for a forgotten one. Proceed with administration taking the next dose in time.</p><p style="text-align:justify"><strong>&nbsp;If you stop taking L-Cet</strong></p><p style="text-align:justify">Stopping treatment should have no negative effects. Symptoms may return, but they should not be any worse than they were prior to the treatment.</p><p style="text-align:justify">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>4. Possible side effects</strong></p><p style="text-align:justify"><strong>&nbsp;</strong>Like all medicines, L-Cet can cause side effects, although not everybody gets them.</p><p style="text-align:justify">Commonly (1% to 10 %), mainly mild to moderate side effects such as dry mouth, headache, tiredness and somnolence/drowsiness have been reported. Uncommon (0.1 % to 1 %), side effects such as exhaustion and abdominal pain have been observed. Other side effects such as palpitations, increased heart rate, convulsions, paraesthesia (abnormal feelings of the skin), dizziness, visual disturbances, blurred vision, painful or difficult urination, oedema, pruritus (itchiness), rash, urticaria (swelling, redness and itchiness of the skin), skin eruption, shortness of breath, weight increase, muscular pain, aggressive or agitated behaviour, hallucination, depression, hepatitis, abnormal liver function, vomiting and nausea, have also been reported.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) may cause allergic reactions (possibly delayed).</p><p style="text-align:justify">At the first signs of a hypersensitivity reaction, stop taking L-Cet and tell your doctor. Hypersensitivity reaction symptoms may include: swelling of the mouth, tongue, face and/or throat, breathing or swallowing difficulties (chest tightness or wheezing), hives, sudden fall in blood pressure leading to collapse or shock, which may be fatal.</p><p style="text-align:justify">If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store L-Cet</strong></p><p>Do not store above 30&ordm;C.</p><p>Protect from light and moisture.</p><p>Keep out of the reach and sight of children.</p><p>Do not use L-Cet after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not use 3 months after first opening.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>L-Cet contains</strong></p><p>1 ml of oral solution contains 0.5 mg levocetirizine dihydrochloride.</p><p>The other ingredients are sodium acetate, glacial acetic acid, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), glycerol, maltitol (E965), saccharin sodium, tutti frutti flavouring agent (triacetin (E1518) and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What L-Cet looks like and contents of the pack 
The oral solution is a clear, colorless liquid presented in a glass bottle. The tutti frutti taste is obtained through the addition of small amounts of a flavouring agent. The bottle of solution is labelled and provided in a carton containing also a measuring cup and a patient information leaflet.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p>Oman Pharmaceutical Products Co., LLC, Salalah, Oman</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1. ما هو أل - ست &nbsp;وما هي استخداماته </strong></p><p dir="RTL">ليفوسيترازين هيدروكلوريد هو العنصر النشط في أل ست. أل - ست هو دواء مضاد للحساسية.</p><p dir="RTL">لعلاج علامات المرض (الأعراض) المرتبطة بـ :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية الأنف (بما في ذلك التهاب الأنف التحسسي المستمر)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح القراص (الشرى).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2. قبل </strong><strong>أخذ </strong><strong>أل- ست </strong></p><p dir="RTL"><strong>لا تأخذ أل- ست </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشكو من حساسية (فرط الحساسية) ليفوسيترازين هيدروكلوريد أو إلى من مضادات الهيستامين أو لميثيل &nbsp;الباراهيدروكسيبنزويت أو لبروبيل الباراهيدروكسيبنزويت أي من المكونات الأخرى من أل ست (انظر &#39;ماذا يحتوي&#39; أل ست)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ضعف شديد في وظائف الكلى (الفشل الكلوي الحاد مع تصفية الكرياتينين أقل من 10 مل / دقيقة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخذ عناية خاصة مع أل - ست</strong></p><p dir="RTL">لا ينصح استخدام أل - ست بالنسبة للرضع والأطفال دون سن 2 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى </strong></p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تأخذ أو تناولت&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخذ أل - ست مع الطعام والشراب </strong></p><p dir="RTL">ينصح بالحذر إذا أخذ أل - ست في نفس الوقت الكحول. في المرضى الذين يعانون حساسية، أخذ سيتيريزين أو ليفوسيتيريزين مع الكحول أو الأدوية الأخرى التي تعمل على الدماغ قد تؤثر على اليقظة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">أخبري طبيبك إذا كنت حاملا، &nbsp;أو تحاولين أن تصبحي حاملا أو تقومين بالرضاعة الطبيعية.</p><p dir="RTL">إسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآليات </strong></p><p dir="RTL">بعض المرضى الذين يعالجون مع أل - ست قد يعانون من النعاس والتعب والإرهاق. يجب أخذ الحذر عند قيادة السيارة أو تشغيل الآلات حنى تتعرف كيفية تأثير هذا الدواء عليك. ومع ذلك، فقد كشفت اختبارات خاصة لا يوجد ضعف في اليقظة العقلية، والقدرة على الاستجابة أو القدرة على القيادة في الأشخاص الأصحاء بعد أخذ ليفوسيتيريزين في الجرعة الموصى بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا الدواء يحتوي المالتيتول. وإذا قيل لك من قبل الطبيب أن لديك التعصب لبعض السكريات، اتصل بطبيبك قبل اتخاذ أل - ست.</p><p>ميثيل الباراهيدروكسيبنزويت و بروبيل الباراهيدروكسيبنزويت قد يسبب الحساسية (ربما متتأخرة)، مثل الصداع، واضطراب في المعدة، والإسهال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3. كيفية </strong><strong>أخذ </strong><strong>أل - ست </strong></p><p dir="RTL">دائما خذ أل - ست تماما كما قال لك طبيبك. يجب عليك التحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة: </strong></p><p dir="RTL">الجرعة المعتادة هي:</p><p dir="RTL">- البالغين والأطفال من سن 6 سنوات: 10 مل من الشراب مرة واحدة يوميا.</p><p dir="RTL">- الأطفال من سن 2-6 سنوات: 2.5 مل من الشراب مرتين يوميا.</p><p dir="RTL">لا ينصح استخدام &nbsp;أل - ست للرضع والأطفال الصغار الذين تقل أعمارهم عن 2 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الجرعة خاصة لفئات معينة من السكان: </strong></p><p dir="RTL">المرضى الذين يعانون من اختلال وظائف الكلى يمكن إعطاءهم جرعة أقل وفقا لشدة مرض الكلى لديهم، وفي الأطفال سيتم اختيار الجرعة على أساس وزن الجسم؛ وسيتم تحديد الجرعة من قبل الطبيب.</p><p dir="RTL">المرضى الذين لديهم ضعف شديد في وظائف الكلى يجب أن لا تأخذ أل - ست.</p><p dir="RTL">ينبغي أن المرضى الذين يعانون من ضعف فقط في وظائف الكبد يجب أن يتناولوا الجرعة الموصوفة المعتادة.</p><p dir="RTL">المرضى الذين لديهم ضعف في كل من الكبد ووظائف الكلى ويمكن إعطاء جرعة أقل اعتمادا على شدة المرض الكلوي، وفي الأطفال سيتم اختيار الجرعة على أساس وزن الجسم؛ وسيتم تحديد الجرعة من قبل الطبيب.</p><p dir="RTL">لا توجد جاجة ضرورية لتكييف الجرعة في المرضى المسنين، شريطة وظيفتها الكلوي أمر طبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف ومتى يجب أن تأخذ أل - ست؟ </strong></p><p dir="RTL">للاستخدام عن طريق الفم فقط.</p><p dir="RTL">يتم توفير جهاز قياس مع العبوة. يمكن أخذ الشراب بدون تخفيف أو مخفف في كوب من الماء.</p><p dir="RTL">أل - ست يمكن اخذه مع أو بدون الطعام.</p><p dir="RTL">يجب أن يتم تناول عن طريق الفم من الدواء بعد التخفيف مباشرة.</p><p dir="RTL">أشطف الكأس بالماء بعد كل استخدام.</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:246.75pt;height:2in;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:\Users\reg05\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="329" height="192" src="file:///C:\Users\reg05\AppData\Local\Temp\msohtmlclip1\01\clip_image002.jpg" /></p><p dir="RTL"><strong>كم من الفترة التي &nbsp;يجب أن تأخذ أل &ndash; ست فيها؟ </strong></p><p dir="RTL">مدة الاستخدام يعتمد على نوع ومدة ومسار الحالة المرضية الخاصة بك ويتم تحديدها من قبل الطبيب المعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تأخذ أكثر مما يجب أل - ست </strong></p><p dir="RTL">إذا كنت تأخذ أل - ست أكثر مما يجب، يمكن أن يحدث النعاس في البالغين. قد تظهر لدى الأطفال في البداية الإثارة والتململ تليها نعاس.</p><p dir="RTL">إذا كنت تعتقد أنك قد تناولت جرعة زائدة من أل - ست، يرجى إخبار الطبيب الذي سوف يقرر ما الإجراء الذي ينبغي اتخاذه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تأخذ أل - ست </strong></p><p dir="RTL">إذا كنت قد نسيت أن تأخذ أل - ست، أو إذا كنت تأخذ جرعة أقل من الموصوفة من قبل الطبيب، لا تأخذ جرعة مضاعفة للتعويض عن الجرعة المنسية. امضي قدما في تناول أخذ الجرعة التالية في الوقت المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول أل - ست </strong></p><p dir="RTL">وقف العلاج ليس لها أي آثار سلبية. قد ترجع الأعراض، لكنها لا ينبغي أن تكون أسوأ مما كانت عليه قبل العلاج.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>4. الآثار الجانبية المحتملة </strong></p><p dir="RTL">مثل جميع الأدوية، ويمكن أل - ست أن يتسبب في آثار جانبية، على الرغم من أن الجميع لا تظهر لديهم.</p><p dir="RTL">الشائعة (1٪ إلى 10٪)، آثار جانبية خفيفة الى معتدلة بشكل رئيسي مثل جفاف الفم، الصداع والتعب والخمول / النعاس تم الإبلاغ عنها. الغير شائعة (0.1٪ إلى 1٪)، لوحظ آثار جانبية مثل الإرهاق وآلام في البطن.</p><p dir="RTL">الآثار جانبية الأخرى مثل الخفقان، وزيادة معدل ضربات القلب، والتشنجات، ومذل (أحاسيس غير طبيعية في الجلد)، والدوخة، واضطرابات بصرية، عدم وضوح الرؤية، تبول مؤلم أو صعب، وذمة، حكة (الحكة)، والطفح الجلدي، الشرى (تورم واحمرار و الحكة في الجلد)، طفح جلدي وضيق في التنفس، وزيادة الوزن، وألم في العضلات، و الارتباك أو السلوك العدواني ، هلوسة، والاكتئاب، والتهاب الكبد، وظائف الكبد غير طبيعية، والتقيؤ والغثيان، تم الإبلاغ عنها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الميثيل الباراهيدروكسيبنزويت (E218) بروبيل الباراهيدروكسيبنزويت (E216) قد يسبب الحساسية (ربما تكون متأخرة).</p><p dir="RTL">عند أول بوادر رد فعل فرط الحساسية، توقف عن اخذ أل - ست وابلغ الطبيب بذلك. قد تتضمن أعراض رد فعل فرط الحساسية: تورم في الفم واللسان والوجه و / أو الحلق، و صعوبات التنفس أو البلع (ضيق الصدر أو الصفير)، قراصية ، وانخفاض مفاجئ في ضغط الدم مما يؤدي إلى انهيار أو صدمة، والتي قد تكون قاتلة.</p><p dir="RTL">إذا كان أي من الآثار الجانبية اصبحت خطيرة ، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5. كيفية تخزين أل - ست </strong></p><p dir="RTL">لا تقم بتخزينه فوق درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يحفظ بعيدا عن الضوء والرطوبة.</p><p dir="RTL">يبقي بعيدا عن متناول وبصر الأطفال.</p><p dir="RTL">لا تستخدم أل - ست بعد تاريخ انتهاء الصلاحية المنصوص علية العبوة &nbsp;والكرتون بعد EXP. تاريخ انتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم المنتج بعد 3 أشهر من فتح العبوة.</p><p>لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>6. المزيد من المعلومات </strong></p><p dir="RTL"><strong>على ماذا يحتوي أل - ست </strong></p><p dir="RTL">1 مل من الشراب الفموي يحتوي على 0.5 ملجم من ليفوسيترازين هيدروكلوريد.</p><p>المكونات الأخرى هي الصوديوم اسيتيت، وحامض الخليك الجليدي، الميثيل الباراهيدروكسيبنزويت (E 218)، بروبيل الباراهيدروكسيبنزويت (E 216)، الجلسرين، المالتيتول (E965)، السكرين الصوديوم، توتي فروتي منكهة (ثلاثي الأستين (E1518) ) والمياه النقية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل و محتويات عبوة&nbsp; أل - ست&nbsp; </strong></p><p dir="RTL">المحلول الفموي عن طريق الفم هو شفاف، عديم اللون يقدم في زجاجة. يتم الحصول على طعم توتي فروتي من خلال إضافة كميات صغيرة من منكهة.&nbsp; زجاجة محلول يوجد عليها بطاقة تعريفية، وتقدم في كل عبوة كرتونية يحتوي أيضا كوب القياس ونشرة معلومات المريض.</p><p dir="RTL"><strong>العبوة:</strong></p><p dir="RTL">زجاجة تحتوي على 100 مل</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة وصاحبة حقوق التسويق </strong></p><p dir="RTL">زينوفا/ الشركة العمانية لمستحضرات الصيدلة ش.م.م</p><p>&nbsp;صلالة، سلطنة عمان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم إعداد النشرة: ديسمبر 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1. Name of the medicinal product
L-Cet 0.5 mg/ml oral solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2. Qualitative and quantitative composition
1 ml of oral solution contains 0.5 mg levocetirizine dihydrochloride.
Sr. No.	Ingredient  Specifications & R.M. Code	Function	Unit Qty mg/ml

01.	Levocetirizine dihydrochloride IHS 	Active pharmaceutical ingredient	0.50 * 
02.	Methyl Hydroxybenzoate Ph.Eur  	Preservative	1.80 * 
03.	Propyl Hydroxybenzoate
Ph.Eur  	Preservative	0.20 * 
04.	Glycerol Ph.Eur 
(Glycerin refined 99.5%)  	Solvent	250.00
05.	Maltitol, Liquid Ph.Eur	Sweetening agent	360.00
06.	Saccharin sodium Ph.Eur	Sweetening agent	0.30
07.	Tutti frutti flavor, Liquid IHS  	Flavoring agent	0.10
08.	Purified water Ph.Eur/USP	Vehicle	Q.S.
09.	Sodium acetate trihydrate Ph.Eur  	Buffering agent	5.00 @
10.	Acetic acid, Glacial Ph.Eur	Buffering agent	5.00 @
* To be added based on calculations.
@ Quantity may vary depending on pH of the product.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3. Pharmaceutical form
Oral solution
Clear and colorless liquid

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4. Clinical particulars</strong></p><p><strong>4.1 Therapeutic indications</strong></p><p>Symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and urticaria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.2 Posology and method of administration</strong></p><p>Instruction for use</p><p>A dosing oral syringe is included in the package. The appropriate volume of oral solution should be measured with the oral syringe, and poured in a spoon or in a glass of water. The oral solution must be taken orally immediately after dilution, and may be taken with or without food.</p><p>Adults and adolescents 12 years and above:</p><p>The daily recommended dose is 5 mg (10 ml of solution).</p><p>Elderly:</p><p>Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Patients with renal impairment below).</p><p>Children aged 6 to 12 years:</p><p>The daily recommended dose is 5 mg (10 ml of solution).</p><p>Children aged 2 to 6 years:</p><p>The daily recommended dose is 2.5 mg to be administered in 2 intakes of 1.25 mg (2.5 ml of solution twice daily).</p><p>Even if some clinical data are available in children aged 6 months to 12 years (see section 4.8, 5.1 and 5.2), these data are not sufficient to support the administration of levocetirizine to infants and toddlers aged less than 2 years. (see also section 4.4).</p><p>Adult patients with renal impairment:</p><p>The dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Description: https://www.medicines.org.uk/emc/images/spc~19877~5~83211.gif"
 style='width:304.5pt;height:39.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:\Users\reg05\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif"
  o:title="spc~19877~5~83211"/>
</v:shape><![endif]--><img width="406" height="53" alt="Description: https://www.medicines.org.uk/emc/images/spc~19877~5~83211.gif" src="file:///C:\Users\reg05\AppData\Local\Temp\msohtmlclip1\01\clip_image001.gif" /></p><p>Dosing Adjustments for Patients with Impaired Renal Function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:452px"><tbody><tr><td style="vertical-align:top"><p>Group</p></td><td style="vertical-align:top"><p>Creatinine clearance (ml/min)</p></td><td style="vertical-align:top"><p>Dosage and frequency</p></td></tr><tr><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&ge;80</p></td><td style="vertical-align:top"><p>5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50 &ndash; 79</p></td><td style="vertical-align:top"><p>5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30 &ndash; 49</p></td><td style="vertical-align:top"><p>5 mg once every 2 days</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>5 mg once every 3 days</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease - Patients undergoing dialysis</p></td><td style="vertical-align:top"><p>&lt; 10-</p></td><td style="vertical-align:top"><p>Contra-indicated</p></td></tr></tbody></table><p>Paediatric patients suffering from renal impairment:</p><p>The dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his body weight. There are no specific data for children with renal impairment.</p><p>Patients with hepatic impairment:</p><p>No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended (see Patients with renal impairment above).</p><p>Duration of use:</p><p>Intermittent allergic rhinitis (symptoms &lt;4days/week or during less than 4 weeks) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear. In case of persistent allergic rhinitis (symptoms &gt;4days/week and during more than 4 weeks), continuous therapy can be proposed to the patient during the period of exposure to allergens. Clinical experience with 5 mg levocetirizine as a film-coated tablet formulation is currently available for a 6-month treatment period. For chronic urticaria and chronic allergic rhinitis, up to one year&#39;s clinical experience is available for the racemate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3 Contraindications
Hypersensitivity to levocetirizine, to any piperazine derivatives, to methyl parahydroxybenzoate, to propyl parahydroxybenzoate, or to any other excipients.
Severe renal impairment at less than 10 ml/min creatinine clearance.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.4 Special warnings and precautions for use</strong></p><p>Precaution is recommended with intake of alcohol (see Interactions).</p><p>The presence of methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed).</p><p>L-Cet contains maltitol: Patients with rare hereditary problems of fructose intolerance should not take this medicine.</p><p>Even if some clinical data are available in children aged 6 months to 12 years (see section 4.8, 5.1 and 5.2), these data are not sufficient to support the administration of levocetirizine to infants and toddlers aged less than 2 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5 Interaction with other medicinal products and other forms of interaction</strong></p><p>No interaction studies have been performed with levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant adverse interactions (with antipyrine, pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, glipizide and diazepam). A small decrease in the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400 mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine administration.</p><p>In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration.</p><p>The extent of absorption of levocetirizine is not reduced with food, although the rate of absorption is decreased.</p><p>In sensitive patients the simultaneous administration of cetirizine or levocetirizine and alcohol or other CNS depressants may have effects on the central nervous system, although it has been shown that the racemate cetirizine does not potentiate the effect of alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.6 Pregnancy and lactation</strong></p><p>For levocetirizine no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant or lactating women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.7 Effects on ability to drive and use machines</strong></p><p>Comparative clinical trials have revealed no evidence that levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive.</p><p>Nevertheless, some patients could experience somnolence, fatigue and asthenia under therapy with levocetirizine. Therefore, patients intending to drive, engage in potentially hazardous activities or operate machinery should take their response to the medicinal product into account.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8 Undesirable effects</strong></p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance &amp; Drug Safety Centre (NPC)</strong><br /><strong>&bull;&nbsp; &nbsp; &nbsp; Fax: +966-11-205-7662<br />&bull;&nbsp; &nbsp; &nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />&bull;&nbsp; &nbsp; &nbsp; Toll free phone: 8002490000<br />&bull;&nbsp; &nbsp; &nbsp; E-mail:&nbsp;</strong><strong>npc.drug@sfda.gov.sa</strong><br /><strong>&bull;&nbsp; &nbsp; &nbsp; Website: </strong><strong>www.sfda.gov.sa/npc</strong></p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Please contact the relevant competent authority</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Clinical studies</u></p><p>In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6 % of these adverse drug reactions were mild to moderate.</p><p>In therapeutic trials, the dropout rate due to adverse events was 1.0% (9/935) with levocetirizine 5 mg and 1.8% (14/771) with placebo.</p><p>Clinical therapeutic trials with levocetirizine included 935 subjects exposed to the drug at the recommended dose of 5 mg daily. From this pooling, following incidence of adverse drug reactions were reported at rates of 1 % or greater (common: &gt;1/100, &lt;1/10) under levocetirizine 5 mg or placebo:</p><table border="1" cellspacing="0" cellpadding="0" style="width:356px"><tbody><tr><td style="vertical-align:top"><p><strong>Preferred Term</strong></p><p><strong>(WHOART)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(n =771)</strong></p></td><td style="vertical-align:top"><p><strong>Levocetirizine 5 mg</strong></p><p><strong>(n = 935)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>25 (3.2 %)</p></td><td style="vertical-align:top"><p>24 (2.6 %)</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>11 (1.4 %)</p></td><td style="vertical-align:top"><p>49 (5.2 %)</p></td></tr><tr><td style="vertical-align:top"><p>Mouth dry</p></td><td style="vertical-align:top"><p>12 (1.6%)</p></td><td style="vertical-align:top"><p>24 (2.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>9 (1.2 %)</p></td><td style="vertical-align:top"><p>23 (2.5 %)</p></td></tr></tbody></table><p>Further uncommon incidences of adverse reactions (uncommon &gt;1/1000, &lt;1/100) like asthenia or abdominal pain were observed.</p><p>The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1 %) under levocetirizine 5 mg than under placebo (3.1%).</p><p><strong><em>Paediatric population</em></strong></p><p>In two placebo-controlled studies in paediatric patients aged 6-11 months and aged 1 year to less than 6 years, 159 subjects were exposed to levocetirizine at the dose of 1.25mg daily for 2 weeks and 1.25mg twice daily respectively. The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.</p><table border="1" cellspacing="0" cellpadding="0" style="width:404px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class and Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(n=83)</strong></p></td><td style="vertical-align:top"><p><strong>Levocetirizine</strong></p><p><strong>(n=159)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3(1.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>1(0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2(1.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Salivary hypersecretion</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Thirst</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hunger</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>2(2.4%)</p></td><td style="vertical-align:top"><p>3(1.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Psychomotor hyperactivity</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disorder</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2(1.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Middle insomnia</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>In children aged 6-12 years double blind placebo controlled studies were performed where 243 children were exposed to 5mg levocetirizine daily for variable periods ranging from less than 1 week to 13 weeks. The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.</p><table border="1" cellspacing="0" cellpadding="0" style="width:434px"><tbody><tr><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (n=240)</strong></p></td><td style="vertical-align:top"><p><strong>Levocetirizine 5mg (n=243)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>5(2.1%)</p></td><td style="vertical-align:top"><p>2(0.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>1(0.4%)</p></td><td style="vertical-align:top"><p>7(2.9%)</p></td></tr></tbody></table><p>As stated in sections 4.2 and 4.4, please note that even if clinical data presented in this section are available in children aged 6 months to 12 years, we do not have sufficient data to support the administration of the product to infants and toddlers aged less than 2 years.</p><p><u>Post-marketing experience</u></p><p>In addition to the adverse reactions reported during clinical studies and listed above, very rare cases of the following adverse drug reactions have been reported in post-marketing experience.</p><p>&bull; Immune system disorders: hypersensitivity including anaphylaxis</p><p>&bull; Psychiatric disorders: aggression, agitation, hallucination, depression</p><p>&bull; Nervous system disorders: convulsion, paraesthesia, dizziness</p><p>&bull; Eyes disorders: visual disturbances, blurred vision</p><p>&bull; Cardiac disorders: palpitations, tachycardia</p><p>&bull; Respiratory, thoracic, and mediastinal disorders: dyspnoea</p><p>&bull; Gastrointestinal disorders: nausea, vomiting</p><p>&bull; Hepatobiliary disorders: hepatitis</p><p>&bull; Renal and urinary disorders: dysuria</p><p>&bull; Skin and subcutaneous tissue disorders: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria</p><p>&bull; Musculoskeletal, connective tissues, and bone disorders: myalgia</p><p>&bull; Investigations: weight increased, abnormal liver function tests</p><p>Methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.9 Overdose</strong></p><p>a) Symptoms</p><p>Symptoms of overdose may include drowsiness in adults and initially agitation and restlessness, followed by drowsiness in children.</p><p>b) Management of overdoses</p><p>There is no known specific antidote to levocetirizine.</p><p>Should overdose occur, symptomatic or supportive treatment is recommended. Gastric lavage should be considered following short-term ingestion. Levocetirizine is not effectively removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5. Pharmacological properties</strong></p><p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: antihistamine for systemic use, piperazine derivative.</p><p>ATC code: R06A E09.</p><p>Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors.</p><p>Binding studies revealed that levocetirizine has high affinity for human H1-receptors (Ki = 3.2 nmol/l). Levocetirizine has an affinity 2-fold higher than that of cetirizine (Ki = 6.3 nmol/l). Levocetirizine dissociates from H1-receptors with a half-life of 115 &plusmn; 38 min.</p><p>After single administration, levocetirizine shows a receptor occupancy of 90% at 4 hours and 57% at 24 hours.</p><p>Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.</p><p>The pharmacodynamic activity of levocetirizine has been studied in randomised, controlled trials:</p><p>In a study comparing the effects of levocetirizine 5mg, desloratadine 5mg, and placebo on histamine-induced wheal and flare, levocetirizine treatment resulted in significantly decreased wheal and flare formation which was highest in the first 12 hours and lasted for 24 hours, (p&lt;0.001) compared with placebo and desloratadine.</p><p>The onset of action of levocetirizine 5 mg in controlling pollen-induced symptoms has been observed at 1 hour post drug intake in placebo controlled trials in the model of the allergen challenge chamber.</p><p>In vitro studies (Boyden chambers and cell layers techniques) show that levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through both dermal and lung cells. A pharmacodynamic experimental study in vivo (skin chamber technique) showed three main inhibitory effects of levocetirizine 5 mg in the first 6 hours of pollen-induced reaction, compared with placebo in 14 adult patients: inhibition of VCAM-1 release, modulation of vascular permeability and a decrease in eosinophil recruitment.</p><p>The efficacy and safety of levocetirizine has been demonstrated in several double-blind, placebo controlled, clinical trials performed in adult patients suffering from seasonal allergic rhinitis, perennial allergic rhinitis, or persistent allergic rhinitis. Levocetirizine has been shown to significantly improve symptoms of allergic rhinitis, including nasal obstruction in some studies.</p><p>A 6-month clinical study in 551 adult patients (including 276 levocetirizine-treated patients) suffering from persistent allergic rhinitis (symptoms present 4 days a week for at least 4 consecutive weeks) and sensitized to house dust mites and grass pollen demonstrated that levocetirizine 5 mg was clinically and statistically significantly more potent than placebo on the relief from the total symptom score of allergic rhinitis throughout the whole duration of the study, without any tachyphylaxis. During the whole duration of the study, levocetirizine significantly improved the quality of life of the patients.</p><p>The paediatric safety and efficacy of levocetirizine tablets has been studied in two placebo controlled clinical trials including patients aged 6 to 12 years and suffering from seasonal and perennial allergic rhinitis, respectively. In both trials, levocetirizine significantly improved symptoms and increased health-related quality of life.</p><p>In children below the age of 6 years, clinical safety has been established from several short- or long -term therapeutic studies:</p><p>- one clinical trial in which 29 children 2 to 6 years of age with allergic rhinitis were treated with levocetirizine 1.25 mg twice daily for 4 weeks</p><p>- one clinical trial in which 114 children 1 to 5 years of age with allergic rhinitis or chronic idiopathic urticaria were treated with levocetirizine 1.25 mg twice daily for 2 weeks</p><p>- one clinical trial in which 45 children 6 to 11 months of age with allergic rhinitis or chronic idiopathic urticaria were treated with levocetirizine 1.25 mg once daily for 2 weeks</p><p>- one long-term (18 months) clinical trial in 255 levocetirizine - treated atopic subjects aged 12 to 24 months at inclusion.</p><p>The safety profile was similar to that seen in the short-term studies conducted in children 1 to 5 years of age.</p><p>In a placebo-controlled clinical trial including 166 patients suffering from chronic idiopathic urticaria, 85 patients were treated with placebo and 81 patients with levocetirizine 5mg once daily over six weeks. Treatment with levocetirizine resulted in significant decrease in pruritus severity over the first week and over the total treatment period as compared to placebo. Levocetirizine also resulted in a larger improvement of health-related quality of life as assessed by the Dermatology Life Quality Index as compared to placebo.</p><p>Chronic idiopathic urticaria was studied as a model for urticarial conditions. Since histamine release is a causal factor in urticarial diseases, levocetirizine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria.</p><p>Pharmacokinetic / pharmacodynamic relationship:</p><p>The action on histamine-induced skin reactions is out of phase with the plasma concentrations.</p><p>ECGs did not show relevant effects of levocetirizine on QT interval.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.2 Pharmacokinetic properties</strong></p><p>The pharmacokinetics of levocetirizine are linear with dose- and time-independent with low inter-subject variability. The pharmacokinetic profile is the same when given as the single enantiomer or when given as cetirizine. No chiral inversion occurs during the process of absorption and elimination.</p><p>Absorption:</p><p>Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after two days. Peak concentrations are typically 270 ng/ml and 308 ng/ml following a single and a repeated 5 mg o.d. dose, respectively. The extent of absorption is dose-independent and is not altered by food, but the peak concentration is reduced and delayed.</p><p>Distribution:</p><p>No tissue distribution data are available in humans, neither concerning the passage of levocetirizine through the blood-brain-barrier. In rats and dogs, the highest tissue levels are found in liver and kidneys, the lowest in the CNS compartment.</p><p>In humans, levocetirizine is 90% bound to plasma proteins. The distribution of levocetirizine is restrictive, as the volume of distribution is 0.4 l/kg.</p><p>Biotransformation:</p><p>The extent of metabolism of levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral dose.</p><p>Due to its low metabolism and absence of metabolic inhibition potential, the interaction of levocetirizine with other substances, or vice-versa, is unlikely.</p><p>Elimination:</p><p>The plasma half-life in adults is 7.9 &plusmn; 1.9 hours. The half-life is shorter in small children.</p><p>The mean apparent total body clearance in adults is 0.63 ml/min/kg. The major route of excretion of levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via faeces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.</p><p>Renal impairment:</p><p>The apparent body clearance of levocetirizine is correlated to the creatinine clearance. It is therefore recommended to adjust the dosing intervals of levocetirizine, based on creatinine clearance in patients with moderate and severe renal impairment. In anuric end stage renal disease subjects, the total body clearance is decreased by approximately 80% when compared to normal subjects. The amount of levocetirizine removed during a standard 4-hour hemodialysis procedure was &lt; 10%.</p><p>Paediatric population:</p><p>Data from a paediatric pharmacokinetic study with oral administration of a single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that Cmax and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison. The mean Cmax was 450 ng/mL, occurring at a mean time of 1.2 hours, weight-normalized, total body clearance was 30% greater, and the elimination half-life 24% shorter in this paediatric population than in adults. Dedicated pharmacokinetic studies have not been conducted in paediatric patients younger than 6 years of age. A retrospective population pharmacokinetic analysis was conducted in 324 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age is expected to result in plasma concentrations similar to those of adults receiving 5 mg once daily.</p><p>Geriatric Patients:</p><p>Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65&ndash;74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age. This finding would also be applicable for levocetirizine, as levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the levocetirizine dose should be adjusted in accordance with renal function in elderly patients.</p><p>Gender:</p><p>Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender. The half-life was slightly shorter in women (7.08 &plusmn; 1.72 hr) than in men (8.62 &plusmn; 1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 &plusmn; 0.16 mL/min/kg) appears to be comparable to that in men (0.59 &plusmn; 0.12 mL/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function.</p><p>Race:</p><p>The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed.</p><p>Hepatic impairment:</p><p>The pharmacokinetics of levocetirizine in hepatically impaired subjects have not been tested. Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of the racemic compound cetirizine as a single dose had a 50% increase in half life along with a 40% decrease in clearance compared to healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3 Preclinical safety data</strong></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction, genotoxicity or carcinogenicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6. Pharmaceutical particulars</strong></p><p><strong>6.1 List of excipients</strong></p><p>Sodium acetate trihydrate (for pH adjustment), Glacial acetic acid (for pH adjustment), Methyl parahydroxybenzoate (E218), Propyl parahydroxybenzoate (E216), Glycerol 85%, Maltitol (E965), Saccharin sodium, Tutti frutti flavor &amp; Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.2 Incompatibilities</strong></p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6.3 Shelf life
2 years.
3 months after first opening.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.4 Special precautions for storage</strong></p><p>Store below 30&deg;C</p><p>Protect from light &amp; moisture</p><p>Keep out of the reach of the children</p><p>Do not use 3 months after first opening of the bottle</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.5 Nature and contents of container</strong></p><p>100 ml amber glass bottle closed with a white polypropylene child-resistant closure in a cardboard box and a patient information leaflet. A dose measuring device is provided with the pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.6 Special precautions for disposal and other handling</strong></p><p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7. 7. MARKETING AUTHORISATION HOLDER
ZYNOVA/OMAN PHARMACEUTICAL PRODUCTS .CO. L.L.C.,
Salalah, Sultanate of Oman. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec 2015 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>